Characteristics of Patients with Diabetes Initiating Sodium Glucose Co-transporter-2 Inhibitors (SGLT2i): Real-World Results from Three Administrative Databases in Japan

Ito, Yuichiro; Schyndle, James Van; Nishimura, Takuya; Sugitani, Toshifumi; Kimura, Tomomi

doi:10.1007/s13300-019-0577-7

Cited by 10 publications

(18 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Based on the results of these key trials, the European Society of Cardiology and the European Association for the Study of Diabetes recommend SGLT2 inhibitors as first-line oral medication for specific T2DM patients, such as those with high-risk or established cardiovascular disease and chronic kidney disease [6]. Accordingly, the use of SGLT2 inhibitors has been rapidly increasing both globally [7], as well as in Japan [8].…”

Section: Introductionmentioning

confidence: 99%

Real-World Evidence for Long-Term Safety and Effectiveness of Ipragliflozin in Japanese Patients with Type 2 Diabetes Mellitus: final Results of a 3-Year Post-Marketing Surveillance Study (STELLA-LONG TERM)

Nakamura

Maegawa

Tobe

et al. 2020

Expert Opinion on Pharmacotherapy

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Real-World Evidence for Long-Term Safety and Effectiveness of Ipragliflozin in Japanese Patients with Type 2 Diabetes Mellitus: final Results of a 3-Year Post-Marketing Surveillance Study (STELLA-LONG TERM)

Nakamura

Maegawa

Tobe

et al. 2020

Expert Opinion on Pharmacotherapy

View full text Add to dashboard Cite

show abstract

“…The base study cohorts were selected as described elsewhere [22]. For this analysis, eligible patients were further selected.…”

Section: Methodsmentioning

confidence: 99%

“…Patients who started ≥ 2 OADs on the index date were excluded. The code list has been described previously [22]. Patients with T2DM were selected by excluding patients diagnosed as “diabetes otherwise specified.” For the I-dataset only, patients who had < 6 month enrollment prior to the index date were excluded from the study cohort.…”

Section: Methodsmentioning

confidence: 99%

“…More data on the clinical effectiveness of SGLT2i treatment in Japanese patients are needed to guide real-life practice and treatment planning. Previously, we reported the characteristics of SGLT2i users in the first 3 years following the launch of SGLT2i in Japan, using data obtained from three large Japan-specific administrative databases [22]. Here, we further examined the changes in clinical measures [HbA1c, body mass index (BMI), estimated glomerular filtration rate (eGFR)] in the first year after treatment initiation among SGLT2i users to expand on the limited data in these areas.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Real-World Effectiveness of Sodium Glucose Co-Transporter-2 Inhibitors in Japanese Patients with Diabetes Mellitus

et al. 2019

Self Cite

View full text Add to dashboard Cite

IntroductionSodium glucose co-transporter-2 inhibitors (SGLT2i) have been on the market for 5 years in Japan. We explored the real-world effectiveness of SGLT2i in Japan.MethodsWe retrospectively analyzed two large Japanese administrative databases from JMDC Inc.: insurance-dataset (I-dataset) and Medical Data Vision Co. Ltd. [hospital-dataset (H-dataset)]. Patients who newly started SGLT2i or other oral antidiabetic drugs (OADs) between 1 April 2014 and 31 March 2016 were selected for this analysis and followed for 1 year from the index date. Changes in glycated hemoglobin (HbA1c), body mass index (BMI), and estimated glomerular filtration rate (eGFR) were evaluated during the 1-year period.ResultsA total of 127,961 patients in the H-dataset and 26,436 in the I-dataset were included in this analysis. Baseline HbA1c, BMI, and eGFR levels tended to be higher in SGLT2i users than in other OAD cohorts. After 1 year, 44.3% (I-dataset) and 53.3% (H-dataset) of SGLT2i users and 33.0–44.2% (I-dataset) and 47.0–58.1% (H-dataset) of other users were still on their medications. The mean HbA1c level decreased by − 0.7 to − 0.9% in SGLT2i users versus − 0.4 to − 1.5% in the other cohorts. The mean BMI decreased by − 0.8 kg/m2 in SGLT2i users whereas the change in other cohorts was − 0.5 to 0.4 kg/m2. No clinically relevant changes in eGFR were observed over the period.ConclusionThis study showed that around half of the SGLT2i users were still on medication after 1 year from treatment initiation. Initiation of SGLT2i was associated with improvement in HbA1c and BMI, with no abnormal changes in renal function observed in the first year following treatment. These findings support the results from clinical trials and will expand the existing evidence of SGLT2i use in real-life practice in Japan.FundingAstellas Pharma Inc., Tokyo, Japan.Electronic supplementary materialThe online version of this article (10.1007/s13300-019-00708-w) contains supplementary material, which is available to authorized users.

show abstract

“…Research carried out using this database includes the following: Factor analysis of outcome 3‐4 Patient characteristics 5‐6 Validations of indices 7 …”

Section: Data Resource Basicsmentioning

confidence: 99%

Data resource profile: JMDC claims databases sourced from Medical Institutions

Nagai¹,

Tsuruo²,

Kodaira³

et al. 2020

J of Gen and Family Med

View full text Add to dashboard Cite

Japan has health insurance provided by the social insurance system 1 (referred to below simply as "health insurance"), and when a citizen is examined and/or treated at a medical institution, he/ she presents to that institution a health insurance certificate containing information identifying him/herself and his/her insurance provider, and he/she is then responsible for only a fixed proportion of the medical expenses. The medical institution invoices the insurance provider for the remainder of the sum, via a claims processing and payment organization, on the basis of information in the health insurance certificate. Health insurance is provided by multiple bodies, on the basis of occupation, geography, and age (eg, elderly and geriatric), as follows: 2 • People aged 75 or older can join the medical care system for the late elderly, administered by local governments. • People less than 75 years old, primarily those who are employees of small, medium-sized, or long-established businesses, and/or are in temporary employment, and their dependents, are covered by health insurance administered by the Japan Health Insurance Association, except for employment-related injury. • People less than 75 years old, primarily those who are employees of large businesses, and their dependents, are covered by health insurance administered by health insurance societies, except for employment-related injury.

show abstract

Characteristics of Patients with Diabetes Initiating Sodium Glucose Co-transporter-2 Inhibitors (SGLT2i): Real-World Results from Three Administrative Databases in Japan

Cited by 10 publications

References 27 publications

Real-World Evidence for Long-Term Safety and Effectiveness of Ipragliflozin in Japanese Patients with Type 2 Diabetes Mellitus: final Results of a 3-Year Post-Marketing Surveillance Study (STELLA-LONG TERM)

Real-World Evidence for Long-Term Safety and Effectiveness of Ipragliflozin in Japanese Patients with Type 2 Diabetes Mellitus: final Results of a 3-Year Post-Marketing Surveillance Study (STELLA-LONG TERM)

Real-World Effectiveness of Sodium Glucose Co-Transporter-2 Inhibitors in Japanese Patients with Diabetes Mellitus

Data resource profile: JMDC claims databases sourced from Medical Institutions

Contact Info

Product

Resources

About